GlassScriptPhysician profile
Lauren A Cameron
NPI 1891054466
$7,033.33
in general payments reported to CMS, 2019-2025
48 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,247 · 2020: $283 · 2021: $469 · 2022: $1,619 · 2023: $1,164 · 2024: $1,132 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324 · Education: $91.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.08 |
| Education | $91.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $981.48 | 2019-2025 | Ubrelvy, Botox, Qulipta |
| Lilly USA, LLC | $724.85 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Teva Pharmaceuticals USA, INC. | $716.17 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Neurocrine Biosciences, INC. | $422.28 | 2019-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $314.47 | 2021-2025 | |
| Genentech USA, INC. | $304.75 | 2020-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Harmony Biosciences LLC | $283.42 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $231.71 | 2019-2025 | Xywav |
| Ucb, INC. | $208.79 | 2019-2025 | Fintepla, Briviact |
| Novartis Pharmaceuticals Corporation | $193.65 | 2019-2020 | |
| Avion Pharmaceuticals | $188.54 | 2022-2023 | Dhivy |
| Axsome Therapeutics, INC. | $186.02 | 2023-2025 | Sunosi |
| Acorda Therapeutics, INC | $163.50 | 2019-2022 | |
| Kyowa Kirin, INC. | $150.77 | 2019-2024 | Nourianz |
| Lundbeck LLC | $145.20 | 2019-2025 | Vyepti, Rexulti |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.